10-Q: DSwiss Inc. Reports Strong Revenue Growth in First Half of 2024, Despite Internal Control Weaknesses

DSwiss Inc. saw a significant increase in revenue and a return to profitability in the first half of 2024, though material weaknesses in internal controls were identified.

Summary

• DSwiss Inc. reported its financial results for the quarter and six months ended June 30, 2024.
• The company experienced a substantial increase in revenue, reaching $1,050,744 for the first six months of 2024, compared to $621,195 for the same period in 2023.
• Gross profit also saw a significant rise, reaching $402,070 for the first half of 2024, up from $173,697 in the first half of 2023.
• DSwiss Inc. achieved a net profit of $198,811 for the six months ended June 30, 2024, a turnaround from a net loss of $28,926 for the same period in 2023.
• The company's cash and cash equivalents increased to $458,293 as of June 30, 2024, compared to $113,543 as of June 30, 2023.
• However, the company identified material weaknesses in its internal controls over financial reporting.

Sentiment

Score: 6

Explanation: The document shows strong financial improvements, but the material weaknesses in internal controls temper the positive sentiment. The company is showing growth but has some significant issues to address.

Positives

• The company experienced a significant increase in revenue and gross profit.
• DSwiss Inc. achieved a net profit, reversing a previous loss.
• The company's cash position improved substantially.
• Operating cash flow turned positive, indicating improved operational efficiency.

Negatives

• The company identified material weaknesses in its internal controls over financial reporting.
• There is inadequate segregation of duties and effective risk assessment.
• There are insufficient written policies and procedures for accounting and financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on improving profitability and continued financial support from shareholders.
• There is a risk that the company may not be able to obtain additional financing if needed, or that such financing may come with undue restrictions or cause substantial dilution for stockholders.
• The identified material weaknesses in internal controls could lead to misstatements in financial reporting.
• The company is exposed to credit risk from accounts receivable, though this is mitigated by credit evaluation processes.
• The company is exposed to exchange rate risk due to fluctuations in the value of the Malaysian Ringgit and Hong Kong Dollar against the US Dollar.

Future Outlook

The company plans to expand its operations globally by forming partnerships with local companies in various countries and intends to primarily utilize social media to reach its customers.

Management Comments

• Management believes the existing shareholders or external financing will provide the additional cash to meet the Company's obligations as they become due.
• Management has identified the following material weaknesses which have caused management to conclude that, as of June 30, 2024, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Industry Context

The company operates in the biotech-nutraceutical and beauty supplies industry, which is experiencing growth, particularly in the Asian market. The company's focus on OEM/ODM services and private label offerings aligns with industry trends towards customized and branded products.

Comparison to Industry Standards

• The company's revenue growth of approximately 69% year-over-year is strong compared to the average growth rate in the nutraceutical and skincare industry, which varies but is generally in the single to low double-digit range.
• The return to profitability is a positive sign, as many smaller companies in this sector struggle to achieve consistent profits.
• However, the identified material weaknesses in internal controls are a concern, as robust controls are essential for maintaining investor confidence and ensuring accurate financial reporting, which is a standard expectation for public companies.
• Compared to larger, established players in the industry, DSwiss is still in a growth phase and is likely to have higher volatility in its financial performance.

Related Party Transactions

• The company had revenue of $3,875 and $45,150 from a related party for the six months ended June 30, 2024 and 2023, respectively.
• The company had general and administrative expenses of $5,200 and $3,000 to a related party for the six months ended June 30, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders will be encouraged by the improved financial performance but concerned about the internal control weaknesses.
• Employees may benefit from the company's growth and expansion.
• Customers may see improved product offerings and services.
• Suppliers may experience increased business opportunities.
• Creditors may view the company as a lower risk due to improved profitability.

Next Steps

• The company needs to address the identified material weaknesses in internal controls.
• The company plans to continue its social media marketing strategy.
• The company intends to form partnerships with local companies to expand globally.

Key Dates

Keywords

biotech, nutraceutical, skincare, OEM, ODM, financial results, revenue growth, profitability, internal controls, material weakness